BR112022010591A2 - Penetração transdérmica modulando junções epiteliais - Google Patents

Penetração transdérmica modulando junções epiteliais

Info

Publication number
BR112022010591A2
BR112022010591A2 BR112022010591A BR112022010591A BR112022010591A2 BR 112022010591 A2 BR112022010591 A2 BR 112022010591A2 BR 112022010591 A BR112022010591 A BR 112022010591A BR 112022010591 A BR112022010591 A BR 112022010591A BR 112022010591 A2 BR112022010591 A2 BR 112022010591A2
Authority
BR
Brazil
Prior art keywords
formulation
transdermal penetration
epithelial junctions
modulating epithelial
skin
Prior art date
Application number
BR112022010591A
Other languages
English (en)
Inventor
FITZSIMMONS Nathan
Beal Ryan
Sand Brandon
Original Assignee
Dyve Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyve Biosciences Inc filed Critical Dyve Biosciences Inc
Publication of BR112022010591A2 publication Critical patent/BR112022010591A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

PENETRAÇÃO TRANSDÉRMICA MODULANDO JUNÇÕES EPITELIAIS. A presente invenção refere-se a modalidades, que incluem uma formulação de distribuição transdérmica e método para distribuição transdérmica de um agente ativo para distribuição sistêmica. Uma formulação pode ser aplicada à pele, unha ou folículo piloso de um indivíduo. Depois de penetrar no estrato córneo, o agente pode passar através de outras camadas da pele como proteínas juncionais e/ou cintos de acto-miosina entre células são modulados. A formulação pode incluir um ou mais agentes para tratar uma doença, mal ou um anestésico para aliviar dor. Alternativamente, ele pode incluir um ou mais nutrientes, vitaminas, minerais ou suplementos para promover a saúde e o bem-estar.
BR112022010591A 2019-12-02 2020-12-02 Penetração transdérmica modulando junções epiteliais BR112022010591A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942465P 2019-12-02 2019-12-02
PCT/US2020/062953 WO2021113409A1 (en) 2019-12-02 2020-12-02 Transdermal penetration by modulating epithelial junctions

Publications (1)

Publication Number Publication Date
BR112022010591A2 true BR112022010591A2 (pt) 2022-08-16

Family

ID=76221943

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010591A BR112022010591A2 (pt) 2019-12-02 2020-12-02 Penetração transdérmica modulando junções epiteliais

Country Status (11)

Country Link
US (1) US20220323344A1 (pt)
EP (1) EP4069210A1 (pt)
JP (1) JP2023503581A (pt)
KR (1) KR20220124695A (pt)
CN (1) CN114929208A (pt)
AU (1) AU2020396955A1 (pt)
BR (1) BR112022010591A2 (pt)
CA (1) CA3162453A1 (pt)
IL (1) IL293391A (pt)
MX (1) MX2022006627A (pt)
WO (1) WO2021113409A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102558352B1 (ko) * 2023-01-13 2023-07-24 주식회사 코스모바이오 대마 추출물을 유효성분으로 포함하는 피부 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3536799A (en) * 1999-04-26 2000-11-10 Lead Chemical Co., Ltd. Percutaneous preparations containing oxybutynin
AU2005275193A1 (en) * 2004-07-15 2006-02-23 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
US10653738B2 (en) * 2014-07-22 2020-05-19 Meridian Research and Development Inc. Topical medications for bruises and burns
WO2016103254A1 (en) * 2014-12-21 2016-06-30 One World Cannabis Ltd Use of cannabis to treat psoriasis
US10383816B2 (en) * 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products

Also Published As

Publication number Publication date
US20220323344A1 (en) 2022-10-13
CA3162453A1 (en) 2021-06-10
CN114929208A (zh) 2022-08-19
EP4069210A1 (en) 2022-10-12
AU2020396955A1 (en) 2022-06-23
WO2021113409A1 (en) 2021-06-10
MX2022006627A (es) 2022-06-27
KR20220124695A (ko) 2022-09-14
IL293391A (en) 2022-07-01
JP2023503581A (ja) 2023-01-31

Similar Documents

Publication Publication Date Title
Bakshi et al. Iontophoretic skin delivery systems: Success and failures
Shivakumar et al. Ungual and transungual drug delivery
Zhou et al. Transdermal delivery of insulin using microneedle rollers in vivo
AR046697A1 (es) Metodo y sistema de administracion transdermica de agente asistido por frecuencia
BR0313474A (pt) dispositivo de distribuição transdérmica de vacina tendo microprotuberáncias revestidas
BRPI0509901A (pt) aparelho e método para liberação transdérmica de agentes com base em fentanila
US12109181B2 (en) Lidocaine patch and methods of use thereof
BR0317743A (pt) Dispositivo de liberação de agente ativo tendo membros de compósito
BRPI0415466A (pt) método e sistema de pré-tratamento para intensificar a distribuição transdérmica de fármacos
BRPI0416822A (pt) método e sistema de liberação de vacina transdérmica com ultra-som
ATE336276T1 (de) Vorrichtung zur manipulation von nadeln oder polierarray
MXPA06013168A (es) Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
EP2001453A4 (en) APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS FOR TREATING OR PREVENTING OSTEOPENIA
BR112022010591A2 (pt) Penetração transdérmica modulando junções epiteliais
BR112021025545A2 (pt) Formulações de penetração transdérmica
TW200738252A (en) Apparatus and method for transdermal delivery of Epoetin-based agents
US20210085945A1 (en) Non-invasive Transportation Method
DE102022128062A1 (de) Plattformtechnologie zur Behandlung von entzündlichen, immunologischen und/oder autoimmunologischen Erkrankungen
BR112022008357A2 (pt) Composições e métodos para a distribuição de canabinoides à pele
Shankar et al. Patches: A Novel approach for development of topical drug delivery system
BRPI0513002A (pt) composição para administração tópica ou transdérmica, e, métodos para tratar fragilidades das unhas, unhas espessas, crescimento anormal de unhas, e secura de pele em um paciente, para aumentar a penetração de um agente bioativo através da unha de um humano ou animal de sangue quente, para suprir um agente bioativo transdermicamente, e para produzir uma composição para suprimento transdérmico de um agente bioativo
Ghadge Transdermal Drug Delivery System
Gupta Transdermal drug delivery system
Condon et al. Management of toxicities related to intravenous administration of epidermal growth factor inhibitors
Stegemann Considerations for topical and transdermal drug delivery in older adults

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]